IRD insider transactions
Opus Genetics Inc. (IRD) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for IRD
- SEC Form 4 filed by Rodgers Richard J4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Manuso James S J4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Benton Susan4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Gallagher Cam4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Graves Adrienne L4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Bennett Jean4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Ainsworth Sean4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Schachle Joseph K4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Zaremba Rabourn Amy4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Magrath George4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 4 filed by Jayagopal Ashwath4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Scientific & Dev. Ofc. Jayagopal Ashwath covered exercise/tax liability with 5,313 shares, decreasing direct ownership by 1% to 520,494 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- President Yerxa Benjamin R was granted 400,000 shares, increasing direct ownership by 125% to 719,005 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Operating Officer Schachle Joseph K was granted 250,000 shares, increasing direct ownership by 459% to 304,500 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Head of Fin. Quality Assurance Zaremba Rabourn Amy was granted 86,500 shares, increasing direct ownership by 81% to 193,128 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George was granted 483,639 shares, increasing direct ownership by 37% to 1,775,293 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Scientific & Dev. Ofc. Jayagopal Ashwath was granted 400,000 shares, increasing direct ownership by 318% to 525,807 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Financial Officer Gagnon Robert E. was granted 400,000 shares, increasing direct ownership by 200% to 600,000 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Head of Fin. Quality Assurance Zaremba Rabourn Amy covered exercise/tax liability with 3,390 shares, decreasing direct ownership by 3% to 106,628 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Head of Fin. Quality Assurance Zaremba Rabourn Amy covered exercise/tax liability with 3,950 shares, decreasing direct ownership by 3% to 110,018 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Gallagher Cam was granted 67,000 shares, increasing direct ownership by 3% to 1,991,430 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Manuso James S J was granted 31,188 shares, increasing direct ownership by 12% to 292,951 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Graves Adrienne L was granted 23,643 shares, increasing direct ownership by 30% to 103,147 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Bennett Jean was granted 21,127 shares, increasing direct ownership by 10% to 234,652 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Ainsworth Sean was granted 42,507 shares, increasing direct ownership by 17% to 297,325 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Gallagher Cam bought $323,693 worth of shares (164,000 units at $1.97) and was granted 33,000 shares, increasing direct ownership by 6% to 1,924,430 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Foundation Fighting Blindness Retinal Degeneration Fund sold $8,600,000 worth of shares (4,000,000 units at $2.15) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Amendment: Chief Executive Officer Magrath George covered exercise/tax liability with 30,350 shares, decreasing direct ownership by 2% to 1,291,654 units (SEC Form 4)4/A - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George covered exercise/tax liability with 30,350 shares, decreasing direct ownership by 2% to 1,291,654 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- President Yerxa Benjamin R covered exercise/tax liability with 23,795 shares, decreasing direct ownership by 7% to 319,005 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Financial Officer Gagnon Robert E. was granted 200,000 shares (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SEC Form 3 filed by new insider Gagnon Robert E.3 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Gallagher Cam was granted 869,565 shares, increasing direct ownership by 92% to 1,810,430 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Ainsworth Sean was granted 86,956 shares, increasing direct ownership by 52% to 254,818 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Foundation Fighting Blindness Retinal Degeneration Fund converted options into 6,927,419 shares (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Rodgers Richard J was granted 79,504 shares, increasing direct ownership by 33% to 318,655 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Manuso James S J was granted 79,504 shares, increasing direct ownership by 44% to 261,763 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Graves Adrienne L was granted 79,504 shares (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Gallagher Cam was granted 79,504 shares, increasing direct ownership by 9% to 940,865 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Benton Susan was granted 79,504 shares, increasing direct ownership by 57% to 219,527 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Bennett Jean was granted 79,504 shares, increasing direct ownership by 59% to 213,525 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Ainsworth Sean was granted 79,504 shares, increasing direct ownership by 90% to 167,862 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George was granted 392,157 shares, increasing direct ownership by 42% to 1,322,004 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Gallagher Cam was granted 784,314 shares, increasing direct ownership by 1,018% to 861,361 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Operating Officer Schachle Joseph K was granted 52,500 shares, increasing direct ownership by 2,625% to 54,500 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SVP of Finance Zaremba Rabourn Amy was granted 39,500 shares, increasing direct ownership by 53% to 113,968 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George was granted 330,697 shares, increasing direct ownership by 55% to 929,847 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Financial Officer Jhaveri Nirav S. was granted 52,500 shares, increasing direct ownership by 37% to 194,293 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Scientific & Dev. Ofc. Jayagopal Ashwath was granted 52,500 shares, increasing direct ownership by 72% to 125,807 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SVP of Corp. Dev. Hoffmann Bernhard was granted 29,500 shares, increasing direct ownership by 19% to 185,446 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Financial Officer Jhaveri Nirav S. covered exercise/tax liability with 8,207 shares, decreasing direct ownership by 5% to 141,793 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Scientific & Dev. Ofc. Jayagopal Ashwath covered exercise/tax liability with 5,193 shares, decreasing direct ownership by 7% to 73,307 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SVP of Finance Zaremba Rabourn Amy covered exercise/tax liability with 8,190 shares, decreasing direct ownership by 10% to 74,468 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SVP of Corp. Dev. Hoffmann Bernhard covered exercise/tax liability with 6,751 shares, decreasing direct ownership by 4% to 155,946 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Manuso James S J was granted 50,222 shares, increasing direct ownership by 38% to 182,259 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Director Bennett Jean was granted 34,021 shares, increasing direct ownership by 34% to 134,021 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George bought $97,600 worth of shares (100,000 units at $0.98), increasing direct ownership by 20% to 599,150 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George was granted 6,200 shares, increasing direct ownership by 1% to 499,150 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- President Yerxa Benjamin R bought $9,834 worth of shares (10,000 units at $0.98), increasing direct ownership by 3% to 342,800 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- Chief Executive Officer Magrath George bought $101,158 worth of shares (100,000 units at $1.01), increasing direct ownership by 25% to 492,950 units (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)